Basel/Switzerland and Bridgewater NJ/USA, 16 June 2008 -- Speedel Holding Ltd. (SWX: SPPN) highlighted today that it is actively participating in Hypertension 2008, a joint meeting of the International Society of Hypertension (ISH) and the European Society of Hypertension (ESH), held from 14-19 June 2008 in Berlin, Germany. At the meeting, which is expected to attract over 7000 senior scientists and physicians from around the world, researchers from Speedel and academia will be presenting pre-clinical and clinical data relating to the company's product candidates SPP635 (a second generation renin inhibitor in development for patients with diabetes)[2],[3] and SPP301 (an endothelin receptor A antagonist in development for diabetic kidney disease)[4],[5],[6].
